Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $38.38, for a total value of $767,600.00. Following the sale, the executive vice president directly owned 120,000 shares in the company, valued at approximately $4,605,600. The trade was a 14.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $39.39 on Wednesday. The company’s fifty day moving average price is $38.49 and its 200-day moving average price is $36.86. The stock has a market cap of $22.74 billion, a PE ratio of 29.84, a price-to-earnings-growth ratio of 2.05 and a beta of 0.47. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma PLC has a 12 month low of $25.01 and a 12 month high of $41.24.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The company had revenue of $609.29 million during the quarter, compared to analyst estimates of $765.01 million. On average, equities analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Institutional Trading of Royalty Pharma

A number of institutional investors have recently made changes to their positions in RPRX. CWM LLC raised its holdings in shares of Royalty Pharma by 1.5% during the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 281 shares during the last quarter. Augustine Asset Management Inc. raised its stake in Royalty Pharma by 4.4% during the 2nd quarter. Augustine Asset Management Inc. now owns 6,722 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 283 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Royalty Pharma by 9.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 289 shares during the period. Hudson Bay Capital Management LP lifted its holdings in shares of Royalty Pharma by 1.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 289 shares during the period. Finally, Merit Financial Group LLC boosted its stake in shares of Royalty Pharma by 3.5% in the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock worth $323,000 after buying an additional 306 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. TD Cowen raised their price objective on Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Morgan Stanley reduced their price target on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Weiss Ratings lowered Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective on the stock. Finally, Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Royalty Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.